Company: IMRX
Filing Date: 2025-09-25
Form Type: 8-K
Source: 0001104659-25-093436
Chunk: 1

Company: Immuneering Corp
Filing Date: 2025-09-25
Form: 8-K
Item: Item 1.01
Chunk 1
---
 constitutes a Qualified Public Offering.
Accordingly, pursuant to the Purchase Agreement, subject to the closing of the Offering and the other conditions set forth therein
the Investor has agreed to purchase from the Company, and the Company has agreed to issue and sell to the Investor, an aggregate of
2,708,559 shares of Class A common stock at the closing of the Private Placement. The closing of the Private Placement is contingent upon the
closing of the Offering.

The closing of the Offering and the closing of the Private Placement
are expected to occur concurrently on or about September 26, 2025, subject to the satisfaction of customary closing conditions.

The
Company expects to receive net proceeds from the Offering of approximately $164.1 million, after deducting underwriting discounts
and commissions and estimated offering expenses payable by the Company, and excluding any exercise of the Underwriters' option to purchase additional shares. In addition, the Company expects to receive net proceeds
from the Private Placement of approximately $23.3 million, after deducting estimated private placement fees payable by the Company. The Company intends to use the net proceeds of
the Offering and the Private Placement to advance the preclinical and clinical development of its product candidates and for working
capital and other general corporate purposes. Based on its current business plans, the Company believes that its cash and cash
equivalents and marketable securities, together with the net proceeds from the Offering and the Private Placement (and excluding net proceeds from any exercise of the Underwriters' option to purchase additional shares of our common stock), will be
sufficient to fund its development activities and other operations into 2029.

The Underwriting Agreement contains customary representations, warranties
and covenants by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including
for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations,
warranties and covenants contained in the Underwriting Agreement were made solely for the benefit of the parties thereto and may be subject
to limitations agreed upon by the contracting parties. Accordingly, the Underwriting Agreement is incorporated herein by reference only
to provide investors with information regarding the terms of the Underwriting Agreement and not to provide investors with any other factual
information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company’s periodic
reports and other filings with the Securities and Exchange Commission.

The foregoing description of the Underwriting Agreement is